stockrowAstraZeneca PLC
AZN Healthcare Drug Manufacturers General
AstraZeneca PLC’s revenue for fiscal 2025 (year ended December 2025) was $58.7 billion, up 8.63% from fiscal 2024.
- Revenue
- +6.70%
- EPS
- +22.5%
- Free cash flow
- +1.99%
- Total debt
- +1.75%
Quarter to September 2026, against a year earlier
Follow AZN
Alert me
AstraZeneca PLC (AZN) EPS (diluted)
AstraZeneca PLC's EPS (diluted) for fiscal 2025 was $6.55, up 45.4% from $4.50 in fiscal 2024. Over the twelve months to 30 September 2026 it was $7.06. Over the past ten years it has ranged from $0.08 (fiscal 2021) to $6.55 (fiscal 2025) — the current reading is the highest in ten years. EPS (diluted) has risen for 4 consecutive fiscal years. AstraZeneca PLC ranks 3rd of 20 Drug Manufacturers General companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $6.55 | 45.44% |
| FY2024 | $4.50 | 17.83% |
| FY2023 | $3.82 | 80.19% |
| FY2022 | $2.12 | 2,550.00% |
| FY2021 | $0.08 | (96.72%) |
| FY2020 | $2.44 | 139.22% |
| FY2019 | $1.02 | (40.00%) |
| FY2018 | $1.70 | (28.57%) |
| FY2017 | $2.38 | (13.77%) |
| FY2016 | $2.76 | 23.21% |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $2.00 | 24.06% |
| Jun 2026 | $1.61 | (18.27%) |
| Mar 2026 | $1.97 | 32.71% |
| Dec 2025 | $1.48 | (8.37%) |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| AMGN Amgen Inc. compare | $17.24 |
| AZN AstraZeneca PLC | $7.06 |
| ABBV AbbVie Inc. compare | $5.81 |
| NVS Novartis AG compare | $5.24 |
| BMY Bristol Myers Squibb Company compare | $4.51 |
| NVO Novo Nordisk A/S compare | $4.09 |
| MRK Merck & Co., Inc. compare | $0.97 |
| PFE Pfizer Inc. compare | $0.71 |
| GILD Gilead Sciences, Inc. compare | −$3.16 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on AZN
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement